Both the oral and patch forms come with strong warnings against combining<unk>  with drugs that could produce serotonin syndrome, such as SSRIs and the cough medicine dextromethorphan.<unk>  in combination with the opioid analgesic pethidine is not recommended, as it can lead to severe adverse effects. Several other synthetic opioids such as tramadol and methadone, as well as various triptans, are contraindicated due to potential for serotonin syndrome. Birth control pills containing ethinylestradiol and a progestin increase the bioavailability of<unk>  by 10- to 20-fold. High levels can lead to loss of MAO-B<unk> ectivity, and<unk>  may begin inhibiting MAO-A as well. This increases susceptibility to side effects of non-selective MAOIs, such as tyramine-induced hypertensive crisis and serotonin toxicity when combined with serotonergic medications. Both forms of the drug carry warnings about food restrictions to avoid hypertensive crisis that are associated with MAO inhibitors. The patch form was created in part to overcome food restrictions; clinical trials showed that it was successful. Additionally, in post-marketing surveillance from April 2006 to October 2010, only 13<unk> f-reports of possible hypertensive events or hypertension were made out of 29,141 exposures to the drug, and none were accompanied by objective clinical data. The lowest dose of the patch method of delivery, 6 mg/24 hours, does not require any dietary restrictions. Higher doses of the patch and oral formulations, whether in combination with the older non-selective MAOIs or in combination with the reversible MAO-A inhibitor moclobemide, require a low-tyramine diet.
Selegiline
Rasagiline
Perhexiline
Bedaquiline
Deutetrabenazine
Rimonabant
Belinostat
Tetrabenazine